2017

MHRA and WHO Geneva Joint Inspection approvals

2016

US FDA approval for two plants in India (Maneesh Unit – II and Svizera)

2012

Manufacturing Assets – in India, US, accredited by global agencies like FDA and UK MHRA.

Proven management track record of strategic foresight and smart execution From contract manufacturing to straddling the entire value chain, via organic and inorganic routes in < 10 years

Poised for substantial growth, with key drivers being:

• Domestic Branded formulation and FMCG offerings
• Improving fundamentals of overseas assets
• Group synergies

2006

International Patents for Anti-TB formulations in a single dose sachet. Built USFDA compliant manufacturing facility at Himachal Pradesh.

2005

Acquisition of ‘Phaarmasia' Hyderabad , a recognized manufacturing facility for Oral – Contraceptives

2004

Launch Of 4 Fixed Dose Combination In Sachet

4 million cases cured in 4 years as a sole supplier to WHO GDF

4 FDC product approved by WHO GENEVA for worldwide program. Svizera was only supplier to WHO for first four years.

2003

First Time In The World Amoxicillin Clavulanate With Lactic Acid Bacillus For The First Time In The World WHO-Geneva Approval

2002

Started supplying Anti-TB drug in 77 countries WHO- Global Drug Facility

2001

4 FDC tab for TB approved by WHO GENEVA for worldwide program. Svizera was only supplier to WHO for first four years.

2000

First 3 FDC tab for TB was launched

1999

Commenced dedicated Anti-TB mfg facility. First 4 FDC tab for TB was successfully developed

1998

Tie up with Medical Export Group, The Netherlands

The same business is now regrouped as Svizera Europe as a Joint Venture with one of founders of MEG

1994

Exports commenced

1993

Partnered with H&H to develop and manufacture their derma products

(H&H is now No. 2 derma company in India).

All their products till 2011 were developed and manufactured by Maneesh.

1992

WHO GMP for the first Manufacturing facility in Mumbai